Clinical Trial Update: Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD) [Phase 1]

View source ↗

Summary

Phase 1 study of KT-621 in adults with atopic dermatitis reported safety, pharmacokinetics, pharmacodynamics, and early clinical activity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• KT-621

Snippet

Sponsor: Kymera Therapeutics, Inc. | Conditions: Atopic Dermatitis | Phase 1 | Status: COMPLETED